Afrikaans
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

AI Helps Write
AI Helps Write

Wang Liang

Titel: Hoofgeneesheer
Posisie: Afdelingshoof
Persoonlike Profiel: Hoofgeneesheer, Professor, PhD-toesighouer, tans die Direkteur van die Hematologie-afdeling van Peking Tongren-hospitaal. Hy het in 2010 gegradueer aan die Peking Union Mediese Kollege, met 'n hoofvak in Kliniese Geneeskunde in die agtjaarstelsel, en die Doktorsgraad in Geneeskunde verwerf. Hy is al meer as 10 jaar betrokke by die diagnose en behandeling van hematologiese gewasse (limfoom, veelvuldige myeloom, ens.) en het ryk kliniese ervaring en hoë akademiese prestasies in die diagnose en behandeling van verskillende tipes limfome en myelome, en spesialiseer in geteikende immunoterapie, chemoterapie, CAR-T-selterapie, hematopoïetiese stamseloorplanting, en lei die ontwikkeling van multidissiplinêre diagnose en behandeling (MDT). Sy hoofnavorsingsbelangstellings is geteikende immunoterapie en die ondersoek na die middelweerstandsmeganisme van limfoom, en hy het 'n aantal Nasionale Natuurwetenskapstigtings van China gelei. Hy het meer as 40 professionele artikels gepubliseer, insluitend meer as 30 SCI-geïndekseerde artikels, wat gepubliseer is in Lancet Haematology, Journal of Hematology & Oncology, Leukemia, Clinical Cancer Research, Cancer Treatment Reviews, Cancer Therapy Reviews, en ander tydskrifte en vaktydskrifte. Hy het gepubliseer in Lancet Haematology, Journal of Hematology & Oncology, Leukemia, Clinical Cancer Research, Cancer Treatment Reviews, Cancer, British Journal of Cancer, Annals of Hematology, en Leukemia & Lymphoma. Hy is die mederedakteur van Standard Leukemia Diagnosis and Treatment, Standard Multiple Myeloma Diagnosis and Treatment, en Medical Oncology. Hy is bekroon met die "Respect for Life-2017 Glory to Healers-Youth Innovation Award", die "Tongren Elite"-toekenning in 2020, die "Tongren Hospital Outstanding Young Talent"-toekenning in 2020, en die eerste "Tongren Hospital Outstanding Young Talent"-toekenning in 2020. Tongren Hospital Outstanding Young Talent” in 2020, '35 Young Oncologists Under 35 with the Most Potential in China'. Akademiese Affiliasies: Jong Lid van die Hematologie-tak van die Chinese Mediese Vereniging; Staande Lid van die Limfoom-Immunoterapie-komitee van die Beijing Cancer Prevention and Control Society; Staande Lid van die Mieloomkomitee van die China Medical Education Association; Kenner van die National Natural Science Foundation of China. Hy is 'n mede-redakteur van Aging Pathobiology and Therapeutics, 'n redaksielid van die Chinese Journal of Cancer Prevention and Control, 'n jong redaksielid van Concord Medical Journal, en 'n resensent van Journal of Hematology & Oncology en Cancer Biology & Medicine.

Wang Liang